Reviva Pharmaceuticals Holdings, Inc.
RVPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001742927
No open-market purchases or sales by Reviva Pharmaceuticals Holdings, Inc. insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $3.67K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Reviva Pharmaceuticals Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Reviva Pharmaceuticals Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bhat Laxminarayan | President and CEO | – | Mar 20, 2026 | 1 |
| Narayan Prabhu | Chief Financial Officer | 100,000 | Mar 20, 2026 | 1 |
| Saxena Parag | Director | – | Dec 19, 2025 | 1 |
| Funtleyder Leslie D. | Director | – | Dec 19, 2025 | 1 |
| Patel Purav | Director | 43,547 | Dec 19, 2025 | 1 |
| Margolin Richard A | Director | – | Dec 19, 2025 | 1 |
| Vedanta Partners, LLC | 10% Owner | – | Nov 22, 2023 | 0 |
| Vedanta Associates, L.P. | 10% Owner | – | Nov 22, 2023 | 0 |
| Beta Operators Fund, L.P. | 10% Owner | – | Sep 12, 2022 | 0 |
| Vedanta Associates-R, LP | 10% Owner | – | Sep 12, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2022 (view filing) | Nov 18 | 3 days | Patel PuravDirector | PPurchaseCommon Stock, par value $0.0001 per share | +3.00K | $4.69 | +$14.1K | +7.4%43.5K after | |
| Oct 3, 2022 (view filing) | Sep 30 | 3 days | Narayan PrabhuChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +50.0K | $1.66 | +$83.0K | +100.0%100.0K after | |
| Sep 12, 2022 (view filing)4:34 PM ET | Sep 8 | 4 days | Saxena Parag and 4 others10% Owner | PPurchase | +2.77M | $1.27 | +$3.50M | –513.8K after | Derivative4 lots |
| Jun 30, 2022 (view filing) | Jun 30 | Same day | Narayan PrabhuChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 per share | +50.0K | $1.21 | +$60.5K | New position50.0K after |